Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers

Sci Rep. 2022 Sep 29;12(1):16294. doi: 10.1038/s41598-022-20747-x.

Abstract

Several factors related to anti-spike(S) IgG antibody titers after mRNA COVID-19 vaccination have been elucidated, but the magnitude of the effects of each factor has not been fully understood. This cross-sectional study assessed anti-S and anti-nucleocapsid (N) antibody titers on 3744 healthy volunteers (median age, 36 years; IQR, 24-49 years; females, 59.0%) who received two doses of mRNA-1273 or BNT162b2 vaccine and completed a survey questionnaire. Multiple regression was conducted to identify factors associated with antibody titers. All but one participant tested positive for anti-S antibodies (99.97%). The following factors were independently and significantly associated with high antibody titer: < 3 months from vaccination (ratio of means 4.41); mRNA-1273 vaccine (1.90, vs BNT162b2); anti-N antibody positivity (1.62); age (10's: 1.50, 20's: 1.37, 30's: 1.26, 40's: 1.16, 50's: 1.15, vs ≧60's); female (1.07); immunosuppressive therapy (0.54); current smoking (0.85); and current drinking (0.96). The largest impact on anti-S IgG antibody titers was found in elapsed time after vaccination, followed by vaccine brand, immunosuppressants, previous SARS-CoV-2 infection (anti-N antibody positive), and age. Although the influence of adverse reactions after the vaccine, gender, smoking, and drinking was relatively small, they were independently related factors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273 / administration & dosage
  • 2019-nCoV Vaccine mRNA-1273 / adverse effects
  • 2019-nCoV Vaccine mRNA-1273 / immunology
  • Adult
  • BNT162 Vaccine / administration & dosage
  • BNT162 Vaccine / adverse effects
  • BNT162 Vaccine / immunology
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19 Vaccines* / adverse effects
  • COVID-19 Vaccines* / immunology
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Cross-Sectional Studies
  • Female
  • Healthy Volunteers
  • Humans
  • Immunization Schedule
  • Immunoglobulin G* / blood
  • Immunosuppressive Agents
  • Japan / epidemiology
  • Male
  • Middle Aged
  • Seroepidemiologic Studies
  • Vaccination
  • Young Adult

Substances

  • COVID-19 Vaccines
  • Immunoglobulin G
  • Immunosuppressive Agents
  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine